Legal Representation
Attorney
Thomas E. Zutic
USPTO Deadlines
Next Renewal Deadline
39 days remaining
Non-Final Action E-Mailed
Due Date
August 15, 2025
Extension Available
Until November 15, 2025
Application History
11 eventsDate | Code | Type | Description |
---|---|---|---|
Jun 18, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
Jun 17, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
Jun 17, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Jun 17, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
May 15, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN |
May 15, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED |
May 15, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
May 9, 2025 | DOCK | D | ASSIGNED TO EXAMINER |
Jan 12, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Jan 12, 2025 | MDSM | E | NOTICE OF DESIGN SEARCH CODE E-MAILED |
Dec 23, 2024 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 035
Business consulting and management in the field of clinical trials, namely, management and compilation of computerized databases in the field of clinical trials for business purposes; Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; consulting services regarding cost containment in the field of clinical trials
Class 042
Providing temporary use of online non-downloadable software for business process management; providing temporary use of online non-downloadable generative AI software to assist businesses with clinical trial design, execution, evaluation, and drafting or related reports; providing temporary use of online non-downloadable software to automate document writing for the design, execution, and evaluation of clinical trials; providing temporary use of online non-downloadable software for business management and optimization purposes using technical data, data modelling, AI modelling, and algorithmic processes; providing technical consulting services to businesses in the field of clinical trial optimization, optimizing resource utilization, and improving success rates; providing scientific and technological consulting services for others with regard to the design, planning, management, and optimization of scientific research and clinical trials; consulting services for others in the field of design, planning, and implementation project management of clinical trials
Additional Information
Design Mark
The mark consists of the stacked words "BIOPHARMA , above "DEVELOPMENT AI", which is, in turn, above "BY BCG X", all to the right of a box design containing a circle and two arcs.
Color Claim
Color is not claimed as a feature of the mark.
Pseudo Mark
BIOPHARMA DEVELOPMENT AI BY BOSTON CONSULTING GROUP X
Classification
International Classes
035
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
BIOPHARMA DEVELOPMENT AI